Bortezomib Clonmel 2.5 mg/ml Solution for Injection
Authorisation PA0126/297/001 · Clonmel Healthcare Ltd
- Licence holder
- Clonmel Healthcare Ltd (all products →)
- Active substance
- Bortezomib
- Clinical trials
- 95 clinical trials →
- Dosage form
- Solution for injection
- Routes of administration
- Intravenous use, Subcutaneous use
- ATC codes
- L01XX, L01XX32
- First authorised
- 20/04/2018
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Hybrid application (Article 10(3) of Directive No 2001/83/EC)
Bortezomib: supply and approvals
16 authorised products on the HPRA list contain Bortezomib. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 18 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 18 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 18 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 8 years (since 20 April 2018). The HPRA list marks it as marketed in Ireland.
Other medicines with Bortezomib in Ireland
15 other products on the HPRA list contain Bortezomib, from 11 licence holders; 3 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Bortezomib 2.5 mg/ml solution for injection | EVER Valinject GmbH | National authorisation (PA) | Marketed |
| Bortezomib 3.5 mg powder for solution for injection | MSN Labs Europe Limited | National authorisation (PA) | Marketed |
| Bortezomib Rowex 3.5 mg Powder for solution for injection | Rowex Limited, | National authorisation (PA) | Marketed |
| Bortezomib 1 mg powder for solution for injection | Aspire Pharma (Malta) Limited | National authorisation (PA) | Not marketed |
| Bortezomib 2.5 mg powder for solution for injection | Aspire Pharma (Malta) Limited | National authorisation (PA) | Not marketed |
| Bortezomib 3.5 mg powder for solution for injection | Aspire Pharma (Malta) Limited | National authorisation (PA) | Not marketed |
| Bortezomib 3.5 mg powder for solution for injection | Reddy Holding GmbH | National authorisation (PA) | Not stated |
| Bortezomib Accord 1 mg Powder for solution for injection | Accord Healthcare S.L.U. | Centralised EU authorisation | Not stated |
| Bortezomib Accord 2.5 mg/ml Solution for injection | Accord Healthcare S.L.U. | Centralised EU authorisation | Not stated |
| Bortezomib Accord 3.5 mg Powder for solution for injection | Accord Healthcare S.L.U. | Centralised EU authorisation | Not stated |
| Bortezomib Biotech Pharma 3.5 mg powder for solution for injection | Target Healthcare Limited | National authorisation (PA) | Not marketed |
| Bortezomib Fresenius Kabi 3.5 mg powder for solution for injection | Fresenius Kabi Deutschland GmbH | Centralised EU authorisation | Not stated |
Other substances in ATC group L01XX
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 21 other active substances share the group L01XX with this product:
Topotecan (as hydrochloride) (4) · Topotecan hydrochloride (4) · Hydroxycarbamide (4) · Irinotecan hydrochloride trihydrate (4) · Ixazomib citrate (3) · Rucaparib camsylate (3) · Anagrelide hydrochloride monohydrate (2) · Olaparib (2) · Arsenic trioxide (2) · Idelalisib (2) · Anagrelide (1) · Eribulin mesylate (1) · Carfilzomib (1) · Mitotane (1) · Pentostatin (1) · Sonidegib (1) · Recombinant l-asparaginase (1) · Bexarotene (1) · Ps-341 as boronic acid (bortezomib) (1) · Anagrelide hydrochloride (1) · and 1 more
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
Clonmel Healthcare Ltd holds 429 products on the HPRA list, with 174 different active substances; 325 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.